Comparison
While Kisspeptin is a key regulator of the hypothalamic–pituitary–gonadal axis, controlling puberty and fertility; kisspeptin-10 also inhibits trophoblast invasion and tumor metastasis in experimental models339199, PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101.
While Kisspeptin works as a family of peptides (eg, kisspeptin-10, -13, -14, -54) derived from the KISS1 precursor that activate G-protein–coupled receptor KISS1R (GPR54), triggering GnRH release and regulating pubertal onset and reproductive axis activity339199, PT-141 is the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101.
Kisspeptin is 10 amino acids long, whereas PT-141 is shorter as it has a length of 7 amino acids. Kisspeptin is made up of a sequence of Tyrosine, Asparagine, Tryptophan, Asparagine, Serine, Phenylalanine, Glycine, Leucine, Arginine, Tyrosine. PT-141 is made up of a sequence of sequence data not available in the current dataset.
Kisspeptin
KISS1
PT-141
POMC